Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

The National Parkinson Foundation Invests in the Future of Parkinson's Research

Support Provided for the Next Generation of Movement Disorder Neurologists

MIAMI,FL — Continuing its commitment to invest in the future of Parkinson's research, the National Parkinson Foundation (NPF) announced today two new awards to support promising young Parkinson's disease researchers. With the support of The McCamish Charitable Fund, NPF awarded a fellowship for training neurologists in the field of movement disorders and a research grant to help young faculty to accelerate their scientific careers. 

"Today, young scientists are under more pressure than ever before.  Awards like these are critical in helping to encourage the next generation to pursue careers in scientific innovation in the treatment of Parkinson's disease," said Michael Okun, MD, NPF's National Medical Director. "The lab breakthroughs happening now will rely on the next generation of scientists to usher them through the FDA process and into widespread adoption."

The 2015 NPF McCamish Fellowship Award was presented to Joash T. Lazarus, MD, by the HFM Foundation. Dr. Lazarus is currently chief resident in neurology at Emory University School of Medicine in Atlanta, GA, an NPF Center of Excellence. He was nominated by Stewart Factor, DO, Director of the Emory NPF Center of Excellence. The two-year clinical and research fellowship in movement disorders totals $120,000. 

"Due to the constriction in availability of research funding, it is increasingly difficult for young researchers to begin their careers with new ideas," said Peter Schmidt, PhD, NPF's Chief Information Officer and Vice President of Research and Professional Programs. "The best investment in future research innovation is to provide the support necessary for a young researcher to set aside time to conduct research."

The 2015 NPF McCamish Young Investigator Award was presented to James W. Maas, MD, PhD, by the MPM Foundation. Dr. Maas is currently an Assistant Clinical Professor in the department of neurology at University of California, San Francisco (UCSF), an NPF Center of Excellence. He was nominated by Michael Aminoff, MD, Director of the UCSF NPF Center of Excellence. The year-long research award totals $25,000. 

NPF's Center of Excellence network, which includes Emory and UCSF, features world-renowned Parkinson's specialists focused on reaching across patient and professional communities to change the course of Parkinson's disease. The network serves more than 50,000 individuals diagnosed with Parkinson's. NPF has designated 41 Centers of Excellence around the world. To view a full listing of centers, visit www.parkinson.org/coe

About Parkinson's Disease (PD)
Affecting an estimated one million Americans and four to six million worldwide, PD is the second most common neurodegenerative disease after Alzheimer's and is the 14th leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression) as well as non-motor symptoms (e.g., depression and anxiety A feeling of nervousness, worried thoughts and physical distress.). There is no cure for PD and 60,000 new cases are diagnosed each year in the United States alone.

Monday, March 2, 2015
Parkinson’s Foundation Moving Day Walks Fund Local Parkinson’s Programs in Seven Cities for Spring 2018
Friday, February 16, 2018

NEW YORK & MIAMI, FEBRUARY 16, 2018 — The Parkinson’s Foundation is proud to announce that Moving Day, A Walk for Parkinson’s, has funded more than $17 million in mission services to make life better for people living with Parkinson’s disease (PD).

Terranova’s Stephen Bittel Donates $450,000 to Parkinson’s Foundation to Support Expansion of Centers of Excellence Network
Thursday, February 1, 2018

MIAMI – February 1, 2018 – The Parkinson’s Foundation today announced that Stephen Bittel, chairman and founder of Terranova, has made a $450,000 donation to support the expansion of the foundation’s Centers o

Largest Clinical Study of Parkinson’s Disease Reaches 10,000-Patient Milestone, Reveals Critical Learnings
Wednesday, January 10, 2018

NEW YORK & MIAMI - January 10, 2018 - The Parkinson’s Foundation today announced the enrollment of the 10,000th Parkinson’s patient and the discovery of critical new learnings in what represents the largest clinical study of Parkinson’s disease in history.

Parkinson's Foundation Mourns the Loss of Harold P. Kravitz and His Daughter, the Honorable Shelley J. Kravitz
Friday, January 5, 2018

Today we mourn the loss of two prominent figures in the history of the Parkinson's Foundation: Harold P. Kravitz, Esq. and his daughter, the Honorable Shelley J. Kravitz.

Parkinson's Foundation Mourns the Loss of Robert Burke, MD
Friday, January 5, 2018

The Parkinson’s Foundation mourns the loss of Robert Burke, MD, professor of Neurology at Columbia University, a Parkinson’s Foundation Center of Excellence. He was a former member of the Parkinson’s Disease Foundation (PDF) Scientific Advisory Board and led the PDF Research Center at Columbia.

Parkinson's Foundation Study Finds Gender Disparities in Caregiving, with Women at a Disadvantage
Monday, December 4, 2017

Largest Clinical Study Tracking Parkinson’s Patients Over Time Shows Women with Parkinson’s Have Fewer Caregiving Resources than Men with Parkinson’s

Parkinson’s Foundation Invests $60,000 to Develop Innovative Models of Patient Engagement
Wednesday, November 29, 2017

Six Awards Foster Patient-Driven Parkinson’s Research

Jesse Jackson Diagnosed with Parkinson's Disease
Friday, November 17, 2017

Rev. Jesse Jackson’s announcement today that he has been living with Parkinson’s Disease since 2015 further proves that receiving a diagnosis of Parkinson's is not a death sentence. There are many ways that people living with Parkinson's can control the symptoms of the disease with exercise and physical therapy to help maintain mobility and balance.

Update on Tozadenant Trial for Parkinson’s
Thursday, November 16, 2017

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial.  They concluded that they could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.

Parkinson’s Foundation Adds Marcia Mondavi Borger to Board of Directors
Tuesday, November 14, 2017

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Marcia Mondavi Borger to its Board of Directors.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.